IVA vs. GPCR, CVAC, CALT, DYN, AMPH, NAGE, AUPH, ELVN, ABCL, and WVE
Should you be buying Inventiva stock or one of its competitors? The main competitors of Inventiva include Structure Therapeutics (GPCR), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Dyne Therapeutics (DYN), Amphastar Pharmaceuticals (AMPH), Niagen Bioscience (NAGE), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), and WAVE Life Sciences (WVE). These companies are all part of the "pharmaceutical products" industry.
Inventiva vs. Its Competitors
Structure Therapeutics (NASDAQ:GPCR) and Inventiva (NASDAQ:IVA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.
Structure Therapeutics has a beta of -1.87, indicating that its stock price is 287% less volatile than the S&P 500. Comparatively, Inventiva has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.
Structure Therapeutics has higher earnings, but lower revenue than Inventiva.
Inventiva's return on equity of 0.00% beat Structure Therapeutics' return on equity.
In the previous week, Inventiva had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 2 mentions for Inventiva and 1 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.04 beat Inventiva's score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the media.
91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 9.4% of Structure Therapeutics shares are held by company insiders. Comparatively, 32.0% of Inventiva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Structure Therapeutics currently has a consensus price target of $76.17, indicating a potential upside of 269.40%. Inventiva has a consensus price target of $10.40, indicating a potential upside of 239.87%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Structure Therapeutics is more favorable than Inventiva.
Summary
Structure Therapeutics and Inventiva tied by winning 6 of the 12 factors compared between the two stocks.
Get Inventiva News Delivered to You Automatically
Sign up to receive the latest news and ratings for IVA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Inventiva Competitors List
Related Companies and Tools
This page (NASDAQ:IVA) was last updated on 7/4/2025 by MarketBeat.com Staff
Free IVA Stock Alerts